Abilify MyCite®

COMBINATION_PRODUCT2 trials

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions

Bipolar I DisorderMajor Depressive DisorderMental DisorderSchizophrenia

Phase 3

A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®

TerminatedNCT03892889

Otsuka Pharmaceutical Development & Commercialization, Inc.Schizophrenia

Start: 2019-04-29End: 2020-09-29Updated: 2021-09-05

Unknown Phase

A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion

CompletedNCT06372210

Otsuka Pharmaceutical Development & Commercialization, Inc.Bipolar I Disorder, Major Depressive Disorder, Mental Disorder +1

Start: 2023-06-26End: 2023-07-19Updated: 2024-07-31

Related Papers

Safety Evaluation in Iterative Development of Wearable Patches for Aripiprazole Tablets With Sensor: Pooled Analysis of Clinical Trials

JMIR Formative Research2023-09-232 citations

Participant Engagement and Symptom Improvement: Aripiprazole Tablets with Sensor for the Treatment of Schizophrenia.

2022-07-288 citations

Phase 3b Multicenter, Prospective, Open-label Trial to Evaluate the Effects of a Digital Medicine System on Inpatient Psychiatric Hospitalization Rates for Adults With Schizophrenia

The Journal of Clinical Psychiatry2022-04-0717 citations